Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma

• Autor(a) principal: Ferreira Galvo, Flavio Henrique
• Data de Publicação: 2010
• Outros Autores: Medina Pestana, Jose Osmar [UNIFESP], Capelozzi, Vera Luiza
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1007/s00280-009-1167-6; http://repositorio.unifesp.br/handle/11600/32184
• topic: Chemotherapy toxicity; Gemcitabine; Pneumonitis; Gallbladder metastasis; Colon cancer

Gemcitabine is a chemotherapy agent that may cause unpredictable side effects. in this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. A 72-year-old patient was submitted to an elective laparoscopic cholecystectomy, and a tubular adenocarcinoma in the gallbladder was incidentally diagnosed. CT scan and ultrasound before the surgery did not show any tumor. After the surgery a Pet scan was positive for a hot-spot in the left colon. the colonic lesion was conveniently removed and the histology evaluation confirmed the diagnosis of adenocarcinoma tubular. the patient was then submitted to three sections of 1,600 mg/m(2) of gemcitabine with intervals of 1 week. Three weeks later he developed severe respiratory distress. A helicoidal CT scan showed diffuse and severe interstitial pneumonitis, and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug-induced toxicity. the patient presented unfavorable evolution with progressive worsening of respiratory function, hypotension, and renal failure. He died 1 month later in spite of methylprednisolone pulse therapy, large spectrum antimicrobial therapy, and full support of respiratory, hemodynamic and renal systems. Gemcitabine-induced pulmonary toxicity is usually a dramatic condition. Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients.